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Abstract Oesophageal cancer is a disease of dismal 
prognosis. There are variations of epidemiology among 
different ethnic groups and geographic regions. India is 
a country with high incidence. This can be attributed to 
the interplay between environmental, dietary factors and 
life-style of the population of the country. Optimal 
therapeutic strategy for patients with oesophageal cancer 
demands individual consideration. 
Majority of oesophageal cancer patients present at 
an advanced stage of disease. Screening programmes 
or strategies aiming at early diagnosis can improve the 
prognosis; unfortunately this is not cost-effective except 
in very high incidence areas. Accurate staging can help 
select the most appropriate treatments, such as excluding 
those patients with metastatic disease who are unlikely to 
benefi t from surgery, and treating very early lesions with 
endoscopic means. When surgery is indicated, treating 
patient in a high-volume centre can improve the outcome 
and minimise complications. Although surgical resection 
remains the main treatment modality, long-term prognosis 
after surgical resection alone has been suboptimal except 
in those with early disease. Multidisciplinary approaches 
including chemotherapy and radiotherapy with or without 
surgery are increasingly employed for patients with 
advanced disease. Collaboration among surgeons, clinical 
oncologists, radiologists and physicians is of utmost 
importance to achieve the best results. Treatment for patients 
should be individualised to enhance outcome.
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Epidemiology
There have been tremendous improvements in the 
management of oesophageal cancer in the recent three 
decades. However, the prognosis of the disease remains 
poor. Oesophageal cancer is the sixth most common cause of 
death from cancer worldwide [1]. The overall 5-year survival 
rate in most countries is only 10–20% after diagnosis. In 
India, for instance, an average 5-year survival of <12% was 
reported [2]. Late presentation and early spread of disease 
are the major factors responsible. 
The divergence of epidemiology between East and West 
also poses additional challenges. For the last three decades, 
the incidence of oesophageal and gastrooesophageal 
junction adenocarcinoma has increased dramatically in 
western countries, and it has surpassed that of squamous 
cell carcinoma. This latter cell type remains the predominant 
histological type of oesophageal cancer in the East [3, 4]. 
This phenomenon of a rising epidemic in adenocarcinoma 
can be attributed to increase in obesity, gastrooesophageal 
refl ux disease and Barrett’s oesophagus [5]. In Asia, 
the prevalence of obesity and gastrooesophageal refl ux 
disease is much less. It has also been postulated that the 
high prevalence of Helicobacter pylori infection in Eastern 
populations may offer some degree of protection against 
refl ux and the development of Barrett’s oesophagus, thus 
accounting for the difference in cancer cell type [6]. In 
India, there has been no convincing epidemiological data 
to show a signifi cant change of cell type of cancer in the 
recent two decades [7]. Squamous cell carcinoma remains 
the predominant histology in India. 
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There is great variation in the incidence of oesophageal 
cancer in different ethic groups and geographic locations. 
In China, oesophageal cancer is the fourth most common 
cancer and the most common cause of cancer death with 
an age-adjusted mortality of up to 140 per 100,000 [8, 9]. 
The age-standardised incidence rate of esophageal cancer 
in China is 27.4 per 105 individual per year [1]. Central and 
northern parts of China such as Henan and Shanxi provinces 
have a particular higher incidence [10, 11]. Similar to China, 
North-East India has a higher incidence compared to other 
regions of the country [12]. Kashmir valley, for instance, 
has reported age-adjusted incidence rates of 43.6 and 27.9 
per 105 individual per year in men and women, respectively 
[13]. Other regions in the world that have high incidences 
include the Caspian littoral of Iran, Normandy in France 
and Transkei province of South Africa.
The pathogenesis of oesophageal cancer is multifactorial 
and includes environmental carcinogens, life-style, dietary 
habits and genetic factors. Poor nutrition, tobacco smoking, 
betel quid chewing, alcohol consumption are major known 
risk factors [14]. The dietary risk factors, specifi cally 
identifi ed in North-East India are hot salty soda tea, red 
chillies and high-nitrate diet especially locally grown 
Brassica leaves [15]. Hot salty soda tea induces chronic 
irritation of the oesophageal epithelium and predisposes 
carcinogenic substance to initiate tissue-specifi c malignant 
transformation. People who use red chilli pepper in the region 
have a higher risk [13]. The average daily dietary intake of 
nitrate in Kashmir valley is 237 mg which is much higher 
than that reported from most Western countries (Germany 
75 mg/day; Britain 95 mg/day) [13]. Reports from southern 
India suggest that more than 80% of oesophageal squamous 
cell carcinoma patients are chronic tobacco smokers. This 
risk-related to smoking is further potentiated by heavy 
consumption of alcohol and other additional risk factors 
such as nutritional and vitamin defi ciencies [16]. 
Regardless of causation, the differences in epidemiology, 
tumour cell type and patient population characteristics 
have practical implications on treatment strategies. In 
the following sections, we shall discuss the management 
for patients with oesophageal cancer, with particular 
emphasis on stage-directed therapy, options of combined 
treatment modalities and lastly, the ways to achieve 
excellent outcome. 
Diagnosis 
The most common presenting symptom of oesophageal 
cancer patient is progressive dysphagia. In high-risk areas, 
elderly patient who complain of dysphagia should be assumed 
to have oesophageal cancer until proven otherwise. Majority 
of oesophageal cancer patients present with advanced stage 
disease because early cancer is asymptomatic and most 
patients do not seek medical advice until severe dysphagia 
and weight loss have occurred. The rich submucosal 
lymphatics of the oesophagus also facilitate early spread of 
tumour cells. Patients with squamous cell carcinoma and 
adenocarcinoma have different demographics. The former 
group of patients are usually of lower socioeconomic class, 
are blue-collar workers, chronic smokers and consume 
much alcohol; while the latter group of patients are of 
higher socioeconomic class, and have obesity-related 
co-morbid conditions such as gastrooesophageal refl ux 
disease and ischaemic heart disease.
Diagnosing oesophageal cancer at an asymptomatic or 
early stage is crucial in improving prognosis. Population 
screening is possible in high-incidence area like China. 
Abrasive cytology using infl atable balloon in China or 
encapsulated sponge in Japan were reported [17, 18]. 
A 5-year survival rate approaching 90% can be achieved 
when early cancers are identifi ed with these methods 
[19]. Endoscopy and systematic biopsies remain the 
gold standard for diagnosis. Adjunctive techniques such 
as chromoendoscopy with Lugol’s iodine, narrow band 
imaging and autofl uoroscence imaging can aid diagnosis 
of early cancers or even premalignant dysplastic lesions. 
The Barrett’s oesophageal metaplasia-dysplasia-cancer 
sequence allows introduction of surveillance programmes. 
There is evidence that patients with Barrett’s oesophagus 
who are recruited into surveillance programmes have a 
better prognosis than non-surveyed patients [20]. 
Pretreatment evaluation
When a patient has a diagnosis of oesophageal cancer 
confi rmed, the next step is to stage the disease accurately and 
to assess the co-morbid conditions of the patient thoroughly. 
This is crucial in formulating optimal therapeutic strategy. 
With increasing choices and combinations of therapeutic 
options, the treatment for early and advanced cancer should 
be individualised.
Method of staging
The purpose of accurate staging is to plan stage-directed 
therapy. The staging system is based on the American Joint 
Committee on Cancer Staging (AJCC) or the International 
Union Against Cancer (UICC) TNM system. The systems 
are recently modifi ed and shown in Table 1a, 1b and 1c 
[21]. The principle of investigation follows that of the 
staging system, namely, tumour status (T), nodal status 
(N) and presence of distant organ metastasis (M) [21]. The 
algorithm for staging oesophageal cancer patients at the 
authors’ institution is shown in Fig. 1. Esophagogastro-
duodenoscopy, bronchoscopy, percutaneous ultrasound 
of cervical lymph nodes ± fi ne-needle aspiration (FNA) 
cytology and CT scan are routine methods. Bronchoscopy 
is specially indicated for mid and upper third tumours 
because of the anatomical proximity; airway involvement 
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Dysphagia or other suspicious symptoms
Preliminary investigations:
1. Blood tests including full blood count, liver and renal function tests
2. Chest X-ray
3. ECG
4. Nutritional status evaluation including body weight and assessment 
of weight loss
Oesophagogastroduodenoscopy:
1. Obtain tissue for histopathological confi rmation of diagnosis
2. Delineate the level of tumour
3. Insertion of feeding tube for nutrition build up if dysphagia is severe
Evaluation of co-morbid 
condition
Evaluation of tumour 
status
1. Pre-anaesthetic assessment
2. Lung function test
3. Advise to quit smoking and alcohol 
consumption
4. Chest physiotherapy 
5. Consultations to relevant specialties 
for optimisation of comorbidity
1. USG ± FNA of neck 
 (For detection of cervical nodal metastasis)
2. EUS ± guided FNA
 (For delineate the T stage, presence of celiac, perigastric, 
peritumoural and perioesophageal lymph node metastasis; 
i.e. N stage)
3. Bronchoscopy
 (For detection of any tracheobronchial tree invasion; i.e. 
T4 disease, particularly for intrathoracic upper and mid 
third tumours)
4. PET-CT scan of neck, thorax and abdomen with oral and 
intravenous contrast if available, otherwise CT scan alone
5. Barium contrast study
Fig. 1 Investigation algorithm for oesophageal cancer at The University of Hong Kong 
precludes surgical resection. Endoscopic ultrasonography 
(EUS) is readily available in specialised centres and it is 
regarded as the best staging modality for T and N stage. 
The accuracy of determining T stage ranges between 85 
and 90% and N stage ranges 70 and 90% [22, 23]. 2-[18F] 
fl uoro-2-deoxy-D-glucose (FDG) positron-emission 
tomography (PET) scan is becoming more commonly 
utilised especially in detecting distant nodal or organ 
metastasis. Reported sensitivity, specifi city and accuracy 
rates for identifying distant metastasis are 88%, 93% and 
91%, respectively but the accuracy of detecting regional 
nodal disease is still inferior to EUS [24–27]. It has also been 
used to evaluate the response to neoadjuvant chemotherapy 
or chemoradiotherapy [28]. The main value of CT scan is 
to detect distant metastatic or T4 disease. The sensitivity 
of liver metastasis depends on the size of the lesion, 
70–80% for lesion larger than 2 cm and <50% for lesion 
smaller than 1 cm. For T4 disease, obliteration of the fat 
plane between the oesophagus and the aorta, trachea 
and bronchi, and pericardium is suggestive of invasion 
but the paucity of fat in cachectic patients makes this 
criterion unreliable. When the area of contact between the 
oesophagus and the aorta extends for more than 90° of the 
circumference, an 80% accuracy of infi ltration is reported 
but is inferior to that of EUS. Normal size lymph node may 
contain metastatic deposits while enlargement of lymph 
node may be due to infl ammatory reactive response, thus 
the accuracy of CT scan in detecting nodal metastasis is 
suboptimal. Nowadays, CT scan is complimentary to PET 
scan when anatomical enlargement of nodes is correlated 
with metabolic activity. 
Therapeutic strategy
Therapeutic options for oesophageal cancer were limited 
in the past. Both surgical resection and radiotherapy were 
used for the purpose of cure or palliation. Oesophageal 
intubation or stenting was used for palliating dysphagia. 
Treatment strategies are evolving and these include 
refi nement of surgical techniques, more precise 
radiotherapy delivering approach, combination of 
radiotherapy and concurrent chemotherapy, and better 
design of oesophageal stents. The management algorithm 
for oesophageal cancer at the authors’ institution is shown 
in Fig. 2.
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Table 1b Stage grouping of the new AJCC staging system for 
squamous cell carcinoma
Stage grouping: squamous cell carcinoma
Stage T N M G G location
0 Tis/ 
HGD
0 0 1, X Any
Ia 1 0 0 1, X Any
IIB 1 0 0 2–3 Any
2–3 0 0 1, X Lower
IIA 2–3 0 0 1, X Upper, middle
2–3 0 0 2–3 Lower
IIB 2–3 0 0 2–3 Upper, middle
1–2 1 0 Any Any
IIIA 1–2 2 0 Any Any
3 1 0 Any Any
4a 0 0 Any Any
IIIB 3 2 0 Any Any
IIIC 4a 1–2 0 Any Any
4b Any 0 Any Any
Any 3 0 Any Any
IV Any Any 1 Any Any
Location:
Upper or middle - cancers above lower border of inferior pulmonary vein
Lower - below inferior pulmonary vein
Table 1c Stage grouping of the new AJCC staging system for 
adenocarcinoma
Stage grouping: adenocarcinoma
Stage T N M G
0 Tis (HGD) 0 0 1, X
IA 1 0 0 1–2, X
IB 1 0 0 3
2 0 0 1–2, X
IIA 2 0 0 3
IIB 3 0 0 Any
1–2 1 0 Any
IIIA 1–2 2 0 Any
3 1 0 Any
4a 0 0 Any
IIIB 3 2 0 Any
IIIC 4a 1–2 0 Any
4b Any 0 Any
Any 3 0 Any
IV Any Any 1 Any
Table 1a Defi nitions of T, N, M and G of AJCC staging system
Primary tumour (T)
Tx Primary tumour cannot be assessed
Tis Carcinoma in situ / High-grade dysplasia
T1 Lamina propria or submucosa
T1a Lamina propira or muscularis mucosae
T1b Submucosa
T2 Muscularis propria
T3 Adventitia
T4 Adjacent structures
T4a Resectable tumour invading pleura, pericardium, dia-
phragm, or adjacent peritoneum
T4b Unresectable tumour invading other adjacent struc-
tures, such as aorta, vertebral body, trachea, etc.
Regional Lymph Nodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1-2 regional lymph nodes
N2 Metastasis in 3-6 regional lymph nodes
N3 Metastasis in seven or more regional lymph nodes
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Histological Grade (G)
Gx Grade cannot be assessed, stage grouping as G1
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated, stage grouping as G3
Summary of changes of the new AJCC staging system:
1 Tis is redefi ned and T4 is subclassifi ed
2 Regional lymph nodes are redefi ned. N is subclassifi ed according to 
the number of regional lymph nodes containing metastasis
3 M is redefi ned
4 Separate stage grouping for squamous cell carcinoma and 
adenocarcinoma (table 1b & 1c)
5 Stage groupings are reassigned using T, N, M, and G classifi cations
6 Tumour location is simplifi ed, and esophagogastric junction and 
proximal 5cm of stomach are included
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Surgery
Surgical resection for oesophageal cancer was once 
associated with high morbidity and mortality rates. The 
operative mortality rate reported was 29% in the 1970s and 
this improved to 13% in the 1980s [29, 30]. Oesophagectomy 
is a complex procedure and the outcome can be improved 
when performed in high-volume centre [31, 32]. In high-
volume centres, resection mortality rate of 2–3% is achieved 
in recent years [33–36]. The reasons of improvement can be 
attributed to advancement of technology in accurate staging, 
better patient selection for surgical treatment, refi nement of 
surgical technique, better perioperative and intensive care 
and centralisation in specialised units [37]. 
Patient selection
Surgery is justifi ed only when low morbidity and 
mortality rates can be achieved, and when a reasonable 
prognosis is expected. A curative (R0) resection with clear 
resection margin has been persistently shown to be one 
of the most important prognostic factors in oesophageal 
cancer treatment. With the availability of other palliative 
modalities, oesophagectomy with a clear palliative intent 
is infrequently performed. Careful pretreatment evaluation 
of the tumour stage can thus avoid unnecessary palliative 
resection.
Another factor to consider in selecting patients for 
this complex surgery is the patient’s physiological reserve 
and ability to withstand the procedure. This assessment 
is generally based on surgeons’ experience and intuition, 
rather than an exact science, although studies have shown 
that objective scores can help assess operative risk and 
patient selection [38, 39]. Cardiopulmonary function, liver 
and renal function should be stringently evaluated before 
subjecting the patient for this major surgery. Many factors 
have been reported to be associated with increased morbidity 
and mortality rate after oesophagectomy, such as advanced 
age, poor performance status, nutritional depletion, more 
proximally located tumour, poor pulmonary function, liver 
cirrhosis and abnormal cardiac function [39–41]. 
Operative approach
There are many aspects to consider on deciding the operative 
approach, which mainly involves consideration on whether 
a thoracotomy is desirable and the intended extent of 
lymph node dissection. Surgical expertise, experience and 
Oesophageal cancer patient
Staging investigations (Fig. 1)
Unresectable disease Resectable disease
T4 disease
Tracheooesophageal fi stula
Stage IV disease
Distant organ metastasis
Palliation
Endoscopic methods
Select patients with 
radiotherapy ± chemotherapy
R0 resection probable R0 not probable
Risk assessment Chemoradiation
Good 
response
Good risk Poor 
response
Poor risk
Risk assessment 
± resection
Palliation
Defi nitive 
chemoradiation
Radical resection Study protocol neoadjuvant/
adjuvant radiotherapy ± 
chemotherapy
R0 resection: microscopic and macroscopic clearance of tumour. 
Fig. 2 Management algorithm for oesophageal cancer at The University of Hong Kong
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preference are also important factors. All these will affect 
the overall outcome. 
Transthora cic or transhiatal approach 
The controversy on the superiority of transthoracic 
(TTE) or transhiatal (THE) approach in oesophagectomy 
remains unresolved over last few decades. The latter 
method involves a blunt mobilisation of the thoracic 
oesophagus from the abdomen without a thoracotomy; 
oesophageal dissection is mostly a peri-oesophageal one 
with limited lymphadenectomy. Proponents of THE argue 
that the pulmonary complication rate can be reduced by 
avoiding a thoracotomy [42], and the benefi t of extended 
lymphadenectomy is unproved. Advocates of TTE claim 
that the procedure allows more thorough mediastinal 
lymph node dissection, thus improving the staging 
accuracy and overall prognosis [43], low complication and 
mortality rates can also be achieved. When the different 
tumour types between the East and West are considered 
(lower oesophageal adenocarcinoma in the West and more 
proximally located squamous cell cancer in the East), 
the transthoracic access is more appropriate and safer in 
the East. The common practice of more extended 
mediastinal nodal dissection in the East also makes TTE 
the preferred method. In Western countries, both TTE 
and THE have their advocates. However even in the 
Netherlands, a recently published randomised control 
trial comparing TTE and THE for patients with 
adenocarcinoma of the lower oesophagus and cardia 
showed that there was a survival advantage for TTE in those 
with limited nodal disease (1–8 positive nodes), though 
a slightly higher postoperative pulmonary complication 
rate was found [44]. With either approach, the surgical 
procedure should be performed properly and preferably 
in specialised centres, a clear resection at proximal, distal 
and axial margins can provide maximum survival benefi t 
to the patients.
Regardless of whether a transthoracic approach is used, 
the propensity of submucosal spread demands a suffi ciently 
long proximal resection margin; thus for patients with 
upper third tumours, a cervical anastomosis is indicated; 
in patients with middle or lower third tumours, a choice 
exists for an intrathoracic or cervical anastomosis. At the 
authors’ institution, current preference is for tumours at 
any level to have a cervical anastomosis. This maximises 
the proximal resection margin, and also allows the most 
thorough mediastinal lymphadenectomy. In addition, 
most resections are performed using a minimally invasive 
approach, and an intrathoracic anastomosis is technically 
more demanding compared to a simple hand-sewn 
anastomosis in the neck.
Minimally invasive surgery 
Minimally invasive surgery (MIS) has dramatically altered 
surgical practice. Application of MIS in oesophagectomy 
was fi rst introduced by Cuscheri in early 1990s [45]. 
A variety of MIS techniques have evolved but a single best 
method has not been accepted [46]. These include different 
combinations of thoracoscopy, laparoscopy, thoracoscopic-
assistance (with mini-thoracotomy) and laparoscopic-
assistance (with mini-laparotomy). The most popular 
approach is perhaps thoracoscopic oesophageal mobilisation 
with laparotomy [47–50]. The reported advantages of MIS 
include better cosmetic outcome, less blood loss, analgesic 
requirement, pulmonary complication rates, recurrent 
laryngeal nerve injury, shortened intensive care or hospital-
stay. There have been few studies that directly compare the 
open procedure to minimally invasive oesophagectomy; 
conclusive result of which approach is superior is 
lacking. A learning curve does exist for this complicated 
procedure [51]. 
Lymph node dissection/extent of dissection
Related to the THE versus TTE debate detailed above, is the 
controversy related to the extent of lymph node dissection. 
Proponents of extensive lymphadenectomy believe that 
more accurate pathological staging can be achieved, local 
control of the disease is better and long-term survival is 
improved. On the contrary, others claim that extensive 
nodal dissection only leads to stage migration without 
improving the overall prognosis, and should complications 
occur, postoperative recovery and long-term quality-of-life 
are adversely affected. 
Three-fi eld lymph node dissection (3-FL) was pioneered 
in Japan that entails lymph node dissection of the upper 
abdomen, mediastinum and both sides of the neck [52]. 
Although it could be demonstrated a signifi cant proportion 
of patients will have preoperatively unsuspected cervical 
nodes after 3-FL, whether its routine application would 
lead to better prognosis remains controversial. Such high-
risk surgery should only performed in specialised centre. 
Current staging system defi nes regional nodes as extending 
from the neck through the mediastinum to the celiac 
axis. However, most would recommend a two-fi eld 
lymphadenectomy for lower and middle third tumours, 
while additional cervical lymphadenectomy should be 
performed for upper third tumours. There is increasing 
evidence to show that extended lymphadenectomy is related 
to survival. One international multicentre study showed that 
the number of lymph nodes resected was an independent 
prognostic factor in addition to age, gender, cell type, 
presence of nodal metastases, number of nodes involved, 
and depth of tumour invasion [53]. A recent international 
multicentre study shows that in order to maximise survival, 
the optimal number of lymph node that should be dissected 
is related to the T stage: 10 nodes should be resected for 
T1 lesions, 20 for T2, and 30 or more for T3/T4 disease 
[54]. Of course, in practice it is impossible to count the 
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number of nodes removed at the time of surgery, this is 
merely used in retrospect to assess the quality and adequacy 
of lymphadenectomy. One should aim at resecting as 
many regional nodes as possible to provide therapeutic 
benefi t in terms of locoregional disease control and long-
term survival, balancing the extent of lymphadenectomy 
with morbidity.
Combined multimodality treatment
In multimodality treatment, surgery, chemotherapy and 
radiotherapy are combined. Owing to the geographic 
difference in epidemiology and results of locally conducted 
clinical trials, the use of multimodality treatment varies 
among different countries. In the United Kingdom, 
preoperative chemotherapy followed by surgical resection 
is a well accepted treatment whereas in United States, 
chemoradiation is more widely practiced. In Asia, surgical 
resection remains the main treatment strategy in resectable 
cancer although increasingly multimodality treatment is 
being explored. 
In the United Kingdom, the MRC trial (OE02) 
randomised 802 patients to a surgery alone or a preoperative 
chemotherapy (two courses of cisplatin and 5-fl uorouracil 
[5-FU]) followed by surgery group [55]. It demonstrated 
a superior survival in the preoperative chemotherapy plus 
surgery group. This trial has changed practice in the United 
Kingdom, making neoadjuvant chemotherapy a standard-
of-care. Although cisplatin combined with 5-FU is the most 
commonly used regimen, other chemotherapeutic agents 
have been studied. Combination of paclitaxel and platinum 
compounds is given frequently and response rates ranging 
from 40% to 52%, higher than that of cisplatin - 5-FU, 
have been reported. Pathological complete response rate of 
around 15% is obtained, whereas generally a <10% complete 
response rate is seen with cisplatin - 5-FU combinations 
[56, 57]. 
In the United States, chemoradiation has gained 
popularity since the publication of the landmark study 
Radiation Therapy Oncology Group (RTOG 85-01) trial 
of chemoradiation versus radiotherapy in the early 1990s. 
This study demonstrated superiority in local and distant 
control as well as overall survival in patients who received 
chemoradiation than those treated with radiotherapy alone 
[58, 59]. The 5-year survival rate reported in RTOG 85-01 
was 26% for chemoradiation compared with 0% for radiation 
alone. This survival rate was claimed to be comparable to 
surgery alone. Chemoradiation has been recommended 
as an alternative treatment option for surgery particular 
in those with poor surgical risk. Direct comparison with 
surgical resection is lacking; the role of chemoradiation 
as neoadjuvant therapy has been widely investigated 
both for squamous cell carcinoma and adenocarcinoma, 
respectively, the results have been confl icting [60]. It seems 
that for early cancers where a R0 resection can be carried out 
with confi dence, surgical resection alone can be performed. 
In patients with more advanced cancers, neoadjuvant 
therapy is a clear option. In summary, multimodality 
therapy is gaining popularity. How to select the most 
appropriate combination of treatment for individual patient 
remains a challenge. Close collaboration between different 
specialties or regular meetings involving multidisciplinary 
experts probably can help in the therapeutic strategy 
formulation process.
Palliation
The most common symptom that requires palliation 
in advanced staged oesophageal cancer is dysphagia. 
Other symptoms that require palliation include cancer 
pain, odynophagia, malnutrition, or aspiration related 
to presence of tracheooesophageal fi stula. For palliation 
of dysphagia, various endoscopic methods are available 
including placement of an oesophageal prosthesis, laser 
therapy, electrocoagulation, intralesional injection of 
various substances, and photodynamic therapy. The most 
popular is perhaps insertion of self-expanding metallic 
stents (SEMS) [61]. A major advantage of SEMS is 
that it can quickly relieve dysphagia safely. Potential 
complications associated with SEMS are stent migration, 
tumour ingrowth, acid refl ux (if stent is placed across the 
gastrooesophageal junction). Foreign body sensation, 
pain, odynophagia and airway compression are the 
main potential problems if the stenting zone is close to 
the cricopharyngeus. 
Summary
Improvements have been made in the management of 
oesophageal cancer. Therapeutic options are evolving. 
Surgeons play a vital role in the management of this 
disease. How to best integrate surgical resection with 
other non-operative programmes remains a challenge. 
Screening in high incidence area is an approach to achieve 
diagnosis at an early stage that can improve the prognosis 
of this deadly disease. Advancement of technology allows 
more accurate staging and provides guidance on patient 
selection for different therapeutic options. The procedure 
of surgical resection is complicated and centralisation in 
specialised units may reduce the morbidity and mortality 
rates. Extent of surgical resection should be balanced 
between the risk and benefi t. Chemoradiation and other 
non-operative treatment programmes are gaining popularity 
but they are not without risks. Treatment of patient 
should be individualised and close collaboration among 
multidisciplinary specialists in formulating therapeutic 
strategy is the key to achieve success.
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